Search and analyze individual stocks with comprehensive metrics
Zydus Lifesciences Ltd
Fundamental Score
Zydus Lifesciences Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of ZYDUSLIFE across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (21.21%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (24.31%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Operating Margins (25.73%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Attractive Valuation (P/E: 18.74 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Robust Profit Growth (40.92%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (16.92%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Excellent EPS Growth (26.36% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (25.92% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Strong Interest Coverage (23.80x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹12623.10 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (74.99%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
0 factors identified
No significant concerns identified in current analysis.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Zydus Lifesciences Ltd
About ZYDUSLIFE
Business Overview
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopaedic surgery, including pathologies affecting the hip and knee. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.
Company Details
Key Leadership
Corporate Events
Latest News
ZYDUSLIFE Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Zydus Lifesciences Ltd (ZYDUSLIFE)?
As of 20 Jan 2026, 11:13 am IST, Zydus Lifesciences Ltd (ZYDUSLIFE) is currently trading at ₹873.40. The stock has a market capitalization of ₹94.25K (Cr).
Is ZYDUSLIFE share price Overvalued or Undervalued?
ZYDUSLIFE is currently trading at a P/E ratio of 18.74x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Zydus Lifesciences Ltd share price?
Key factors influencing ZYDUSLIFE's price include its quarterly earnings growth (Sales Growth: 16.92%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Zydus Lifesciences Ltd a good stock for long-term investment?
Zydus Lifesciences Ltd shows a 5-year Profit Growth of 25.92% and an ROE of 21.21%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.38 before investing.
How does Zydus Lifesciences Ltd compare with its industry peers?
Zydus Lifesciences Ltd competes with major peers in the Pharmaceuticals. Investors should compare ZYDUSLIFE's P/E of 18.74x and ROE of 21.21% against the industry averages to determine its competitive standing.
What is the P/E ratio of ZYDUSLIFE and what does it mean?
ZYDUSLIFE has a P/E ratio of 18.74x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹19 for every ₹1 of annual earnings.
How is ZYDUSLIFE performing according to Bull Run's analysis?
ZYDUSLIFE has a Bull Run fundamental score of 68.7/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does ZYDUSLIFE belong to?
ZYDUSLIFE operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Zydus Lifesciences Ltd.
What is Return on Equity (ROE) and why is it important for ZYDUSLIFE?
ZYDUSLIFE has an ROE of 21.21%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Zydus Lifesciences Ltd generates profits from shareholders' equity.
How is ZYDUSLIFE's debt-to-equity ratio and what does it indicate?
ZYDUSLIFE has a debt-to-equity ratio of 0.38, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.
What is ZYDUSLIFE's dividend yield and is it a good dividend stock?
ZYDUSLIFE offers a dividend yield of 1.17%, which means you receive ₹1.17 annual dividend for every ₹100 invested.
How has ZYDUSLIFE grown over the past 5 years?
ZYDUSLIFE has achieved 5-year growth rates of: Sales Growth 10.27%, Profit Growth 25.92%, and EPS Growth 26.36%.
What is the promoter holding in ZYDUSLIFE and why does it matter?
Promoters hold 74.99% of ZYDUSLIFE shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is ZYDUSLIFE's market capitalization category?
ZYDUSLIFE has a market capitalization of ₹94254 crores, placing it in the Large-cap category.
How volatile is ZYDUSLIFE stock?
ZYDUSLIFE has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for ZYDUSLIFE?
ZYDUSLIFE has a 52-week high of ₹N/A and low of ₹N/A.
What is ZYDUSLIFE's operating profit margin trend?
ZYDUSLIFE has a 5-year average Operating Profit Margin (OPM) of 25.73%, indicating the company's operational efficiency.
How is ZYDUSLIFE's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 16.92% and YoY Profit Growth of 40.92%.
What is the institutional holding pattern in ZYDUSLIFE?
ZYDUSLIFE has FII holding of 7.34% and DII holding of 10.86%. Significant institutional holding often suggests professional confidence in the stock.